tbuckley/cabot-search huggingface dataset:
Progression free survival (PFS) benefit from first line endocrine based therapies in postmenopausal women with HR+ HER2- metastatic breast cancer (MBC) according to different prognostic subgroups: A combined analysis of data from PALOMA 2, MONALEESA 2, MONARCH 3, FALCON, SWOG and FACT trials
Authors: V. Rossi, D. Giannarelli, P. Berchialla, C. Nisticò, G. Ferretti, S. Gasparro, P. Malaguti, M. Russillo, G. Catania, L. Vigna, R.L. Mancusi, F. Cognetti, A. Fabi
Journal: Annals of Oncology (2018)
MA08.07 Real World Data of Osimertinib in Patients with Central Nervous System (CNS) Metastasis in ASTRIS Korean Subset.
Authors: J. Kang, B.C. Cho, D. Kim, K. Park, J. Lee, S.S. Yoo, S.Y. Lee, C.H. Kim, S.H. Jang, Y. Kim, H. Yoon, S. Kim
Journal: Journal of Thoracic Oncology (2018)
Overweight, obesity and weight gain after breast cancer (BC): A prospective clinical study
Authors: A. Di Meglio, M. El-Mouhebb, S. Michiels, L. Jones, M. Annonay, A. Zingarello, M. Matias, S. Everhard, A.L. Martin, P. Arveux, O. Tredan, P. Soulie, P.H. Cottu, A.H. Partridge, L. Del Mastro, J.A. Ligibel, F. André, I. Vaz-Luis
Journal: Annals of Oncology (2018)
Effectiveness of trastuzumab emtansine (TDM1) in patients with HER2-positive advanced breast cancer (ABC) progressing after taxane plus pertuzumab plus trastuzumab
Authors: B. Conte, A. Fabi, F. Poggio, E. Blondeaux, C. Dellepiane, A. D'Alonzo, A. Staiano, G. Buono, G. Arpino, V. Magri, G. Naso, D. Presti, S. Mura, A. Fontana, F. Cognetti, C. Molinelli, S. Pastorino, C. Bighin, M. Lambertini, L. Del Mastro
Journal: Annals of Oncology (2018)
P1.14-26 Long Term Outcome and Clinicopathological Features of Thymic Carcinoma - A Retrospective Study of 25 Cases at a Single Institution
Authors: H. Tanaka, K. Kaseda, K. Masai, T. Ohtsuka, Y. Hayashi, T. Hishida, H. Asamura
Journal: Journal of Thoracic Oncology (2018)
Abstract #4647: In vivo validation of HectH9 as a cancer target via gene silencing in established orthotopic xenografts.
Authors: Jennyfer Bultinck, Martin Eilers, Michel Aguet
Journal: Cancer Research (2009)

The progressive accumulation of mutations in critical regulators of cell proliferation, survival and differentiation is one of the hallmarks of cancer. It remains however difficult to assess the individual contribution of each oncogenic event in late stage cancer. Therefore, we have established a versatile in vivo platform using lentivirus-transduced human orthotopic xenografts to conditionally regulate expression of putative cancer-relevant genes. Non-invasive luciferase-based imaging allows real-time evaluation of cancer progression. In a proof of principle experiment, we knocked down s-catenin that has been reported to induce cell differentiation of colon cancer cell lines in vitro. Using an adapted version of the two-vector system originally described by Wiznerowicz and Trono (J. Virol. 77, 8957-8961, 2003), regulated knock-down of s-catenin was achieved in established tumor grafts resulting in induction of cell differentiation in areas lacking s-catenin. HectH9 is an E3 ubiquitin ligase that is overexpressed in multiple human tumors. Its expression level correlates with tumor stage, at least in colorectal carcinomas. Following the observation that suppression of HectH9 expression abrogates proliferation of a subset of tumor cell lines (Adhikary et al., Cell 123, 409-421, 2005), HectH9 expression was repressed in established orthotopic xenografts of LS174T human colon cancer cells. Orthotopic engraftment of LS174T cells in the colon of immuno-compromised mice leads to primary tumor formation in the colon with metastasis to the peritoneum, lymph nodes, lung and liver. shRNA-mediated silencing of HectH9 in established colorectal tumors abrogated tumor outgrowth as well as the formation of distal metastasis. Further on the road to preclinical validation of HectH9 as a putative therapeutic target, its tumor selectivity is currently being assessed notably versus primary cells.   Citation Information:  In: Proc Am Assoc Cancer Res; 2009 Apr 18-22; Denver, CO. Philadelphia (PA): AACR; 2009. Abstract nr 4647.
MA08.05 Brain Penetration of Lorlatinib and Cumulative Incidence Rates for CNS and Non CNS Progression from a Phase 1/2 Study
Authors: T. Bauer, A. Shaw, M. Johnson, A. Navarro, J. Gainor, H. Thurm, Y. Pithavala, A. Abbattista, E. Felip
Journal: Journal of Thoracic Oncology (2018)
P2.16-11 Prognostic Role of Combined Pulmonary Fibrosis and Emphysema (CPFE) in Patients with Clinical Stage I Lung Cancer
Authors: Y. Tsutani, T. Tasaki, Y. Handa, D. Ueda, H. Hanaki, Y. Miyata, M. Okada
Journal: Journal of Thoracic Oncology (2018)
OA10.05 An Open-Label, Multicenter, Phase II Single Arm Trial of Osimertinib in NSCLC Patients with Uncommon EGFR Mutation(KCSG-LU15-09)
Authors: J.H. Cho, J. Sun, S. Lee, J.S. Ahn, K. Park, K.U. Park, E.J. Kang, Y.H. Choi, K.H. Kim, H.J.A. An, H.W. Lee, M. Ahn
Journal: Journal of Thoracic Oncology (2018)
Cognitive functions, coping strategies and psychological distress in patients with resected non-advanced cancer receiving chemotherapy: NEOcoping study data
Authors: O. Higuera Gomez, C. Calderón, I. Ghanem, A. Carmona-Bayonas, C. Jara, R. Hernández, B. Castelo, M.M. Muñoz, C. Beato, S. García, E. Martínez, M. Mut, A. Ramchandani Vaswani, M. Mangas, O. Donnay, M.T. García-García, M.C. Soriano, R. Carrión, C. Iglesias Gomez, P. Jimenez Fonseca
Journal: Annals of Oncology (2018)
Arrhythmogenic Right Ventricular Cardiomyopathy: Progress Toward Personalized Management
Authors: Cynthia A. James, Hugh Calkins
Journal: Annual Review of Medicine (2018)

Arrhythmogenic right ventricular cardiomyopathy (ARVC) is an inherited heart disease characterized by fibrofatty replacement of the ventricular myocardium, a high risk of ventricular arrhythmias, and progressive ventricular dysfunction. The clinical course is highly variable, and optimal approaches to management remain undefined. ARVC is associated with pathogenic variants in genes encoding the cardiac desmosome. Genetic testing facilitates identification of at-risk family members, but penetrance of ARVC in pathogenic variant carriers is difficult to predict. Participation in endurance exercise is a known key risk factor. However, there remains significant uncertainty about which family member will develop disease and how best to approach longitudinal screening. Our clinically focused review describes how new insights gained from natural history studies, improved understanding of pathogenic mechanisms, and appreciation of genetic and environmental modifiers have set the stage for developing personalized approaches to managing both ARVC patients and their at-risk family members.
Association of Search Engine Queries for Chest Pain With Coronary Heart Disease Epidemiology
Authors: Conor Senecal, R. Jay Widmer, Lilach O. Lerman, Amir Lerman
Journal: JAMA Cardiology (2018)

Online search for symptoms is common and may be useful in early identification of patients experiencing coronary heart disease (CHD) and in epidemiologically studying the disease.To investigate the correlation of online symptom search for chest pain with disease prevalence of CHD.This retrospective study used Google Trends, a publicly available tool that provides relative search frequency for queried terms, to find searches for chest pain from January 2010 to June 2017 in the United States, the United Kingdom, and Australia. For the United States, results were obtained by state. These data were compared with publicly available prevalence data from the US Centers for Disease Control and Prevention of CHD hospitalizations by state for the same period. The same terms were used to evaluate seasonal and diurnal variation. Data were analyzed from July 2017 to October 2017.Correlation of search engine query for chest pain symptoms with temporal and geographic epidemiology.State-by-state comparisons with reported CHD hospitalization were correlated (R = 0.81; P < .001). Significant monthly variation was appreciated in all countries studied, with the United States, United Kingdom, and Australia showing an 11% to 39% increase in search frequency in winter months compared with summer months. Diurnal variation showed a morning peak for search between local time 6 am and 8 am, with a greater than 100% increase seen in peak searching hours, which was consistent among the 3 countries studied.Relative search frequency closely correlated with CHD epidemiology. This may have important implications for search engines as a resource for patients and a potential early-detection mechanism for physicians moving forward.
OA10.06 A First-in-Human Phase 1 Trial of the EGFR-cMET Bispecific Antibody JNJ-61186372 in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)
Authors: K. Park, M. Ahn, S. Lee, H.R. Kim, M.H. Hong, D. Millington, M. Curtis, S. Triantos, S. Chaplan, N. Haddish-Berhane, R. Knoblauch, Z. Aguilar, S. Laquerre, M. Lorenzi, B.C. Cho
Journal: Journal of Thoracic Oncology (2018)
P2.01-68 Capture-Based Sequencing Depicts Evolution Characteristics of Pulmonary Sarcomatoid Carcinoma
Authors: X. Liu, X. Chen, F. Wang, Z. Xie, C. Xu, H. Wang, L. Chang, X. Xia, Y. Guan, X. Yi, L. Chen
Journal: Journal of Thoracic Oncology (2018)
Interim results of fight-202, a phase II, open-label, multicenter study of INCB054828 in patients (pts) with previously treated advanced/metastatic or surgically unresectable cholangiocarcinoma (CCA) with/without fibroblast growth factor (FGF)/FGF receptor (FGFR) genetic alterations
Authors: A. Hollebecque, M. Borad, V. Sahai, D.V.T. Catenacci, A. Murphy, G. Vaccaro, A. Paulson, D.-Y. Oh, L. Féliz, C. Lihou, H. Zhen, G.K. Abou-Alfa
Journal: Annals of Oncology (2018)
Abstract 16968: PI3Kγ Regulates Cardiac Hypertrophy Through Kinase Independent Mechanism
Authors: Maradumane L Mohan, Elizabeth E Martelli, Manveen K Gupta, Neelakantan T Vasudevan, Sathyamangla V Naga Prasad
Journal: Circulation (2012)

Activation of phosphoinositide 3-kinase α (PI3Kα) by Receptor Tyrosine Kinase (RTK) or PI3Kγ by G-protein coupled receptor (GPCR) inhibits glycogen synthase kinase-3 (GSK-3) via protein kinase B (Akt). We show that in addition to promoting GSK-3 phosphorylation through Akt, PI3Kγ in parallel suppresses PP2A dependent GSK-3 dephosphorylation. This is evidenced by accelerated GSK-3 dephosphorylation in PI3Kγ knock out (PI3Kγ-KO) mice downstream of RTK-PI3Kα-Akt axis despite robust Akt activation by insulin. Moreover, steady state GSK-3 phosphorylation is markedly (80% loss) reduced in PI3Kγ-KO hearts. Consistent with the elevated anti-hypertrophic GSK-3 activity, we observed smaller hearts in PI3Kγ-KO mice (Fig). Assessment of GSK-3 dephosphorylating enzyme protein phosphatase 2A (PP2A) showed significant ∼1.2 fold elevation in PP2A activity and a ∼2.5 fold increase in GSK-3 associated phosphatase activity in PI3Kγ-KO mice. Mechanistically, absence of PI3Kγ results in higher PP2A holoenzyme assembly with GS...
MA05.01 E6508: Phase II Study of Immunotherapy with Tecemotide and Bevacizumab after Chemoradiation in Unresectable Stage III NS-NSCLC
Authors: J. Patel, J. Lee, H. Wagner, D. Carbone, A. Shanker, L. Horn, M. Johnson, D. Gerber, J.J. Liu, M. Das, M. Ali Al-Nsour, C. Dakhil, S. Ramalingam, J. Schiller
Journal: Journal of Thoracic Oncology (2018)
P2.13-05 Real-World Clinical Benefit of Continuing Crizotinib Beyond Progression Disease (CBPD) in Patients with Advanced ALK-Positive NSCLC.
Authors: D. Ma, P. Xing, Q. Wang, X. Hao, M. Wang, Y. Wang, L. Shan, T. Xin, L. Liang, H. Liang, Y. Du, Z. Zhang, J. Li
Journal: Journal of Thoracic Oncology (2018)
Diffuse Myocardial Fibrosis in Children and Adolescents With Marfan Syndrome and Loeys-Dietz Syndrome
Authors: Gauri R. Karur, Joseph J. Pagano, Timothy Bradley, Christopher Z. Lam, Mike Seed, Shi-Joon Yoo, Lars Grosse-Wortmann
Journal: Journal of the American College of Cardiology (2018)
First-line treatment for endocrine sensitive bone-only metastatic breast cancer: Is more always better?
Authors: A. Toss, M. Venturelli, I. Sperduti, C. Isca, E. Barbieri, F. Piacentini, C. Omarini, L. Cortesi, S. Cascinu, L. Moscetti
Journal: Annals of Oncology (2018)
SAKK 17/16 - Lurbinectedin monotherapy in patients with progressive malignant pleural mesothelioma: A multicenter, single-arm phase II trial
Authors: Y. Metaxas, A. Xyrafas, M.T. Mark, M. Pless, M. Frueh, P.R. Froesch, M. Schneider, C. Biaggi Rudolf, F. Grosso, R. von Moos
Journal: Annals of Oncology (2018)
Post hoc responder analysis of health‐related quality of life (HRQL) in patients with metastatic castration‐resistant prostate cancer (mCRPC) receiving cabazitaxel in the phase III PROSELICA and FIRSTANA trials
Authors: A. Thiery Vuillemin, K. Fizazi, O. Sartor, S. Oudard, D. Bury, S. Guillonneau, A. Ozatilgan, M. Eisenberger, J.S. de Bono
Journal: Annals of Oncology (2018)
P2.01-15 A Radiologist-Led Training Workshop for MR Based Normal Tissue and Tumour Delineation for Lung Cancer Radiotherapy.
Authors: S. Brown, M. Dubec, H. Bainbridge, D. Cobben, F. Lalezari, F. Mcdonald, H. Sheikh, C. Van Es, M. Van Herk, C. Faivre-Finn
Journal: Journal of Thoracic Oncology (2018)
Comparative genomics reveals the distinct evolutionary trajectories of the robust and complex coral lineages
Authors: Hua Ying, Ira Cooke, Susanne Sprungala, Weiwen Wang, David C. Hayward, Yurong Tang, Gavin Huttley, Eldon E. Ball, Sylvain Forêt, David J. Miller
Journal: Genome biology (2018)

Despite the biological and economic significance of scleractinian reef-building corals, the lack of large molecular datasets for a representative range of species limits understanding of many aspects of their biology. Within the Scleractinia, based on molecular evidence, it is generally recognised that there are two major clades, Complexa and Robusta, but the genomic bases of significant differences between them remain unclear.Draft genome assemblies and annotations were generated for three coral species: Galaxea fascicularis (Complexa), Fungia sp., and Goniastrea aspera (Robusta). Whilst phylogenetic analyses strongly support a deep split between Complexa and Robusta, synteny analyses reveal a high level of gene order conservation between all corals, but not between corals and sea anemones or between sea anemones. HOX-related gene clusters are, however, well preserved across all of these combinations. Differences between species are apparent in the distribution and numbers of protein domains and an apparent correlation between number of HSP20 proteins and stress tolerance. Uniquely amongst animals, a complete histidine biosynthesis pathway is present in robust corals but not in complex corals or sea anemones. This pathway appears to be ancestral, and its retention in the robust coral lineage has important implications for coral nutrition and symbiosis.The availability of three new coral genomes enabled recognition of a de novo histidine biosynthesis pathway in robust corals which is only the second identified biosynthetic difference between corals. These datasets provide a platform for understanding many aspects of coral biology, particularly the interactions of corals with their endosymbionts.
P1.14-03 Phase II Trial of Amrubicin and Cisplatin Chemotherapy for Invasive Thymoma: WJOG5509L
Authors: K. Kudo, M. Nishio, Y. Shikraisi, A. Ono, I. Okamoto, Y. Iwamoto, Y. Ookuma, K. Okuda, K. Akiyoshi, K. Nishino, S. Mituoka, K. Azuma, K. Ueno, T. Iriki, K. Sugio, Y. Chiba, Y. Ishikawa, K. Nakagawa, N. Yamamoto
Journal: Journal of Thoracic Oncology (2018)
P1.03-09 ROS1 Rearrangement in Pulmonary Sarcomatoid Carcinoma: A Retrospective Study of the Real World
Authors: C. Xu, W. Wang, Y. Zhu, M. Fang, W. Zhuang, Q. Zhang, Y. Chen, Z. Gong, G. Chen, T. Lv, Y. Song
Journal: Journal of Thoracic Oncology (2018)
MA18.09 Predictors of Health Utility Scores (HUS) in Advanced EGFR-Mutated NSCLC
Authors: S. Jiang, M. Hurry, K. Hueniken, M.C. Brown, M. Liang, D. Patel, C. Labbe, L. Eng, H. Naik, P. Bradbury, N. Leighl, F. Shepherd, W. Xu, G. Liu, R. Walton, G. O'Kane
Journal: Journal of Thoracic Oncology (2018)
The combination of TAS-102 and bevacizumab as the third line chemotherapy for metastatic colorectal cancer (TAS-CC3 Study)
Authors: H. Kamiyama, Y. Yoshida, H. Yoshida, C. Kosugi, K. Ishibashi, K. Ihara, M. Takahashi, H. Kuramochi, A. Fukazawa, H. Sonoda, K. Yoshimatsu, A. Matsuda, S. Yamaguchi, H. Ishida, S. Hasegawa, T. Yamada, K. Sakamoto, K. Koda
Journal: Annals of Oncology (2018)
Assessment of cfDNA in patients with metastatic colorectal cancer treated with cetuximab monotherapy
Authors: L. Angus, E.J. van Helden, S.C. van Es, E. Boon, C.M.L. van Herpen, D.J. de Groot, E.G.E. de Vries, C.W. Menke-van der Houven van Oordt, S. Sleijfer, H.M. Verheul, M.P.H.M. Jansen
Journal: Annals of Oncology (2018)
P2.11-21 Factors Predicting Attrition in Community-Based Healthcare Network Lung Cancer Screening Programs
Authors: K. Spiegel, J. Rayburn, C. Wilshire, E. Rauch, J. Handy, C. Gilbert, R. Weerasinghe, G. Grunkemeier, S. Chang, J. Gorden
Journal: Journal of Thoracic Oncology (2018)
P3.01-02 Patients with a Smaller Primary Tumor and Fewer Metastases Could be Cured Even in Advanced Non-Small Cell Lung Cancer
Authors: T. Aoki, N. Okada, K. Enokida, S. Hattori, T. Takeuchi, F. Takahashi, G. Takahashi, K. Harada, J. Tanaka, M. Sato, Y. Horio, H. Takiguchi, H. Tomomatsu, K. Tomomatsu, T. Takihara, K. Niimi, N. Hayama, T. Oguma, T. Urano, K. Asano
Journal: Journal of Thoracic Oncology (2018)
P2.01-12 Ramucirumab+Docetaxel Usage Following Rapid Disease Progression in Real World Advanced Non-Small Cell Lung Cancer Patients
Authors: M. Batus, C. Molife, J. Clarke, V. Stefaniak, K. Winfree, Z. Cui, Y. Han, M. Tawney, P. Bonomi
Journal: Journal of Thoracic Oncology (2018)
Facile Engineering of Long‐Term Culturable Ex Vivo Vascularized Tissues Using Biologically Derived Matrices
Authors: Michael Hu, Amir Dailamy, Xin Yi Lei, Udit Parekh, Daniella McDonald, Aditya Kumar, Prashant Mali
Journal: Advanced Healthcare Materials (2018)

Abstract Recent advances in tissue engineering and 3D bioprinting have enabled construction of cell‐laden scaffolds containing perfusable vascular networks. Although these methods partially address the nutrient‐diffusion limitations present in engineered tissues, they are still restricted in both their viable vascular geometries and matrix material compatibility. To address this, tissue constructs are engineered via encapsulation of 3D printed, evacuable, free standing scaffolds of poly(vinyl alcohol) (PVA) in biologically derived matrices. The ease of printability and water‐soluble nature of PVA grant compatibility with biologically relevant matrix materials and allow for easily repeatable generation of complex vascular patterns. This study confirms the ability of this approach to produce perfusable vascularized matrices capable of sustaining both cocultures of multiple cell types and excised tumor fragments ex vivo over multiple weeks. The study further demonstrates the ability of the approach to produce hybrid patterns allowing for coculture of vasculature and epithelial cell‐lined lumens in close proximity, thereby enabling ex vivo recapitulation of gut‐like systems. Taken together, the methodology is versatile, broadly applicable, and importantly, simple to use, enabling ready applicability in many research settings. It is believed that this technique has the potential to significantly accelerate progress in engineering and study of ex vivo organotypic tissue constructs.
Relationship between apalutamide (APA) exposure and metastasis-free survival (MFS) in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC) from SPARTAN
Authors: M.R. Smith, C. Perez-Ruixo, O. Ackaert, D. Ouellet, C. Chien, H. Uemura, D. Olmos, P.N. Mainwaring, J.Y. Lee, M.K. Yu, J.-J. Perez-Ruixo, E.J. Small
Journal: Annals of Oncology (2018)
Efficacy and safety of crizotinib in previously treated patients (Pts) with ALK+ advanced non-small cell lung cancer (NSCLC) aged ≥65 years (y)
Authors: D. Moro-Sibilot, M.-J. Ahn, B. Halmos, D.-W. Kim, G.J. Riely, A.T. Shaw, P.-C. Yang, S. Lanzalone, A. Polli, K.D. Wilner, J. De Castro Carpeño
Journal: Annals of Oncology (2018)
Abstract 19592: Posterior Leaflet Tethering Correlates With LV Size to MV Ring Mismatch for MV Repair in Ischemic Mitral Regurgitation: Mechanistic and Clinical Insights for Recurrence of Ischemic Mitral Regurgitation Post Restrictive Ring Annuloplasty
Authors: Romain Capoulade, Jessica Overbey, Christos G Mihos, Michael Acker, Gorav Ailawadi, John Alexander, Michael Bowdish, James Gammie, Annetine Gelijns, Paul Grayburn, Serguei Melnitchouk, Robert Michler, Patrick O'Gara, Peter Smith, Cynthia Taub, Judy Hung
Journal: Circulation (2017)

Background: The ratio of LV end-systolic dimension (LVESd)/mitral valve (MV) ring size (LV-MV Ring Mismatch) has been shown to be associated with recurrent ischemic mitral regurgitation (IMR) after...
MA25.10 Complete Response by PET-CT After Radical Treatment in Oligometastatic Non-Small Cell Lung Cancer Predicts Longer Survival
Authors: L.A. Cabrera-Miranda, F. Barron, Z. Zatarain-Barrón, L. Ramírez-Tirado, M. Salinas Padilla, J. Corona-Cruz, A. Cardona, M. Arguelles, F. Maldonado, M. Blake, E. Jiménez-Fuentes, O. Aren, O. Arrieta
Journal: Journal of Thoracic Oncology (2018)
Risk of health-related quality of life events and pulmonary toxicities in recurrent ovarian cancer patients treated with poly adenosine diphosphate ribose polymerase (PARP) inhibitors maintenance
Authors: K.Z. Thein, A. Sultan, M.H. Zaw, M.M. Han, N.H. Yu, H.P. Igid, C. Jones, N. D'Cunha, S. Awasthi, F. Hardwicke
Journal: Annals of Oncology (2018)
Mechanisms of acquired resistance to first-line osimertinib: Preliminary data from the phase III FLAURA study
Authors: S.S. Ramalingam, Y. Cheng, C. Zhou, Y. Ohe, F. Imamura, B.C. Cho, M.-C. Lin, M. Majem, R. Shah, Y. Rukazenkov, A. Todd, A. Markovets, J.C. Barrett, J. Chmielecki, J. Gray
Journal: Annals of Oncology (2018)
P1.01-83 IMpower150: Impact of Chemotherapy Cycles in 1L Metastatic NSCLC in Patients Treated With Atezolizumab + Bevacizumab
Authors: J. Rothenstein, A. Spira, V. Velcheti, R. Natale, M. Kozloff, M. Kosty, J. Goldschmidt, J. Mazieres, S. Ponce Aix, W. Yu, M. Gandhi, A. Lee, G. Shankar, W. Lin, C. Thomas
Journal: Journal of Thoracic Oncology (2018)
P1.01-74 MET Exon 14-Altered Lung Cancers: Central Nervous System (CNS) Metastases and Patterns of CNS Progression on MET Inhibition
Authors: M. Offin, J. Dienstag, O. Wilkins, J. Sabari, A. Ni, D. Feldman, M. Van Voorthuysen, K. Suzawa, H. Yu, G. Riely, M. Arcila, M. Ladanyi, M. Kris, C. Rudin, R. Somwar, B. Li, A. Drilon
Journal: Journal of Thoracic Oncology (2018)